The Treatment of Non-Hodgkin's Lymphomas
DOI:
https://doi.org/10.32635/2176-9745.RBC.1986v32n1.3231Palavras-chave:
Linfomas, Linfomas Não-Hodgkin, Quimioterapia, RadioterapiaResumo
Os linfomas não-Hodgkin são um grupo heterogêneo de doenças. Estudos com marcadores celulares nos últimos 15 anos demonstraram que a maioria dos linfomas de células B no adulto são originários dos linfócitos B, enquanto que a minoria tem a sua origem nos linfócitos T.
Downloads
Referências
Rappaport H. Tumors of the hematopoietic System. In Atlas of Tumor Pathology, Section 3, Fascicle 8, Washington, Doc., U.S. Armed Forces Institute of Pathology, 1986.
Jones SE, Fuks Z, BulI M, et al. Non-Hodgkin's lymphomas IV. Clinicopathologic correlation in 405 cases. Câncer 1973;31: 806-823. DOI: https://doi.org/10.1002/1097-0142(197304)31:4<806::AID-CNCR2820310408>3.0.CO;2-1
Anderson T, DeVita VT, Simon RM, et al. Malignant lymphoma II Prognostic factors and response to treatment of 473 patients at the National Câncer Institute. Câncer 1982; 50: 2708-2721. DOI: https://doi.org/10.1002/1097-0142(19821215)50:12<2708::AID-CNCR2820501203>3.0.CO;2-G
Straus DJ, Filippa DA, Lieberman PH, Koziner B, Thaler HT, Clarkson BD. The non-Hodgkin's lymphomas I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958 and 1969. Câncer 1983; 51: 101-109. DOI: https://doi.org/10.1002/1097-0142(19830101)51:1<101::AID-CNCR2820510121>3.0.CO;2-W
Lukes RJ, Coilins RD. New approaches to the classification of the lymphomata. Brit J Câncer (Suppl II) 1975; 31, 1-28.
Lennert K, Mohri N, Stein H, Kaiserling E, Muller-Hermelink HK. Malignant Lymphomas other than Hodgkin's Disease, Histology, Ultrastructure, Immunology. Springer-Verlag, Berlin, Heidelberg, New York, 1978.
The Non-Hodgkin's Lymphoma Pathologic Project: Writing Committee. National Cancer Institute sponsored study of classifications of Non-Hodgkin s lymphoma. Summary and description of a working formulation for clinical usage Câncer 1982; 49: 2112-2135. DOI: https://doi.org/10.1002/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2
Lieberman DH, Filippa DA, Straus DJ, Thaler HT, Cirrin-cione C, Clarkson BD. An evaluation of malignant lymphomas using three classifications and the working for mulation based on 482 cases with a median follow-up of 11.9 years. Am J Med (In Press) 1986.
Carbone PP, Kaplan HS, Mushoff K, Smithers DW, Tubiana M. Report of the committee on Flodgkin's disease classification. Res Cancer 1971:31: 1860-1861.
Weingrad DN, DeCosse JJ, Shercalock P, Straus D, Lieberman PH, Filippa DA. Primary gastrointestinal lymphoma: A 30-year review. Câncer 1982; 49:1258-1265. DOI: https://doi.org/10.1002/1097-0142(19820315)49:6<1258::AID-CNCR2820490630>3.0.CO;2-4
Weinberg DS, Pinkus GS, Ault Ka. Cytofiuorometric detection of B cell clonal excess: A new approach to the diagnosis of B cell lymphoma. Blood 1984; 63: 1080-1087 DOI: https://doi.org/10.1182/blood.V63.5.1080.1080
Lipton A, Lee BJ. Prognosis of stage I lymphosarcoma and reticulum cell sarcoma. New EngI J Med 1971; 284: 230-233. DOI: https://doi.org/10.1056/NEJM197102042840502
Fuks Z, Kaplan HS. Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas. Radiology 1973; 108: 675-684. DOI: https://doi.org/10.1148/108.3.675
Vokes EE, UItmann JE, Golomb HM, et al. Long-term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol 1985; 3: 1309-1317. DOI: https://doi.org/10.1200/JCO.1985.3.10.1309
Landberg TG, Hakansson LG, Moller TR, et al. CVP-remission maintenance in stage I or II non-Ho,dgkin's lymphoma. Preliminary results of a randomized study. Câncer 1979; 44: 831-838. DOI: https://doi.org/10.1002/1097-0142(197909)44:3<831::AID-CNCR2820440307>3.0.CO;2-S
Monfardini S, Bonfi A, Bonodonna G, et al. Improved five year survival after combined radiotherapy-chemotherapy for stage l-ll non-Hodgkin's lymphoma. Int. J. Radiation Oncology Biol Phys 1980; 6: 125-134. DOI: https://doi.org/10.1016/0360-3016(80)90027-9
Nisse NI, Ersboll J, Hensen HS, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage l-ll non-Hodgkin's lymphoma. Câncer; 52: 1-7.
Miller TP, Jones SE. Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood 1983; 62: 413. DOI: https://doi.org/10.1182/blood.V62.2.413.413
DeVita VT, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet 1975; 1:248-250. DOI: https://doi.org/10.1016/S0140-6736(75)91142-3
Berd D, Corneg J, DeConti RC, Levitt M, Bertino JR, Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemoterapy. Câncer 1975; 35: 1050-1054. DOI: https://doi.org/10.1002/1097-0142(197504)35:4<1050::AID-CNCR2820350406>3.0.CO;2-F
Gaynor ER, UItmann JE, Golomb HM, Sweet DL. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, Oncovin, methotrexate recoverorin, cytosine arabinoside): A 10-year experience in single Institution. J Clin Oncol 1985; 3: 1596-1604. DOI: https://doi.org/10.1200/JCO.1985.3.12.1596
Coitman CA, Dahlberg S, Jones SE, et al.: CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: A twelve year Southwest Oncology Group follow-up. Proc Am Soc Clin Oncol 1986; 5:197.
Koziner B, Littie C, Passe S, et al.: Treatment of advance diffuse histiocytic lymphoma: An analysis of prognostic variables. Cancer 1982; 49: 1571-1586. DOI: https://doi.org/10.1002/1097-0142(19820415)49:8<1571::AID-CNCR2820490809>3.0.CO;2-G
Skarin AT, Canelos GP, Rosenthal DS., et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (m-BACOD) J Clin Oncol 1983; 1:91-98. DOI: https://doi.org/10.1200/JCO.1983.1.2.91
Fisher RI, DeVita VT, Hubbard SM, et al. Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE an MOPP combination. Ann Intern Med. 1983: 98: 304-309. DOI: https://doi.org/10.7326/0003-4819-98-3-304
Laurence J, Coleman M, Allen SL, Silver RT, Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six drug COP-BLAM regimen. Ann Intern Med 1082; 97: 190-195. DOI: https://doi.org/10.7326/0003-4819-97-2-190
Klimo D, Connor JM. MACOP-B Chemoterapy for treatment of diffuse large cell lymphoma. Ann Intern. Med. 1985; 102:596-602. DOI: https://doi.org/10.7326/0003-4819-102-5-596
Skarin A, Canellos G, Rosenthal D., et al. Moderate dose methotrexate (m) combined with bleomycin (B) Adriamycin (A), Cyclophophamide (C), Oncovin (O) and Dexamethasone (D), m-BACOD in advanced diffuse histiocytic lymphoma. Pro Am Soc Clin Oncol 1983; 2:220.
Gulati S, Fredorciu B, Gopal A, et al. Autologous stem cell transplant for poor prognosis diffuse histiocytic lymphoma in Autologous Bone Marrow Transplantation. Proceedings of the First International Symposium. ed. by K.A. Dicke G, Spitzer A., Zander: The University of Texas, M.D. Anderson Hospital and Tumor Institute at Houston. 1985; 75-81.
Al-Katib A, Koziner B, Kurland E, et al. Treatment of diffuse differentiated llympocytic. lymphoma: An analysis of prognostic variables. Cancer 1984; 53: 2004-2411. DOI: https://doi.org/10.1002/1097-0142(19840601)53:11<2404::AID-CNCR2820531107>3.0.CO;2-F
Slater DE, Merteismann R, Koziner B, et al. Lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 57-67. DOI: https://doi.org/10.1200/JCO.1986.4.1.57
Longo DL, Young RC, Hubbard SM., et al. Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med 1984; 100: 651-656. DOI: https://doi.org/10.7326/0003-4819-100-5-651
Osborne CK, Norton L, Young RC, et al. Nodular histiocytic lymphoma; An aggressive nodular lymphoma with potential for prolonged disease-free survival. Blood 1980; 56: 98-103. DOI: https://doi.org/10.1182/blood.V56.1.98.98
Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New EngI J Med, 1984; 311: 1471-1475. DOI: https://doi.org/10.1056/NEJM198412063112303
Hoppe RT, Kaplan HS, Rosenberg SA, Brow BW. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: A preliminary report of a randomized trial comparing single agent chemotherapy and whole body irradiation. Blood 1981; 58: 592-598. DOI: https://doi.org/10.1182/blood.V58.3.592.bloodjournal583592
Paryani SB, Hoppe RT, Cox Rs, Colby TV, Kaplan HS. The role of radiation therapy in the management on stage III follicular lymphomas. J. Clin. Oncol. 1984; 2: 841 848. DOI: https://doi.org/10.1200/JCO.1984.2.7.841
Portiock CS, Rosenberg SA. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 1979; 90: 10-13. DOI: https://doi.org/10.7326/0003-4819-90-1-10
Diggs CH, Wiernik PH, Ostrow SS. Nodular lymphoma. Prolongation of survival by complete remission. Cancer Clin Trials 1981; 4: 107-114.
Kempi S, Cirrincione C, Myer J, et al. Combined modality therapy of advanced nodular lymphomas (NL); The role of non-specific immunotherapy (or BV) as an importante determinant of response and survival. Survival Proc Am Soc. Clin. Oncol 1983; 2:56.
Straus DJ, Recht L, Rodgers LO, Posner JB. Central Nervous System (CNS) involvement in non-Hodgkin's lymphoma (NHL); analysis of clinical features and treatment in 96 patients. Proc Am Soc Clin Oncol 1984. 3: 247.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
